Understanding how low oxygen levels affect oesophagogastric cancer
Hypoxia Driven Metabolic Response in Oesophagogastric Adenocarcinoma
Imperial College London · NCT06669663
This study is testing how low oxygen levels in tumors affect the behavior of oesophagogastric cancer in patients to find out if it can help improve treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Imperial College London (other) |
| Locations | 1 site (London) |
| Trial ID | NCT06669663 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with oesophagogastric adenocarcinoma to investigate the metabolic responses triggered by hypoxia, or low oxygen levels, in tumors. It aims to analyze how these hypoxic conditions contribute to the aggressiveness and treatment resistance of the cancer. Patients will be administered pimonidazole hydrochloride to assess the extent of hypoxia in their tumors, which may reveal important insights into their prognosis and potential treatment options. The study seeks to improve understanding of the relationship between tumor hypoxia and cancer outcomes.
Who should consider this trial
Good fit: Ideal candidates include males and females aged 18-90 with biopsy-proven oesophageal or gastric adenocarcinoma undergoing surgical resection or staging laparoscopy.
Not a fit: Patients with non-adenocarcinoma cancers, recent antibiotic therapy, previous resections, allergies to pimonidazole, or those unable to provide consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better prognostic tools and targeted therapies for patients with oesophagogastric cancer.
How similar studies have performed: While the specific approach of this study may be novel, there is existing literature indicating that understanding tumor hypoxia can lead to improved treatment strategies in cancer care.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and females aged 18-90 years. * Patients with biopsy proven oesophageal or gastric adenocarcinoma who are undergoing either surgical resection or staging laparoscopy. Exclusion Criteria: * Non-adenocarcinoma cancer (e.g. oesophageal squamous cell carcinoma) * Antibiotic therapy within the last 8 weeks * Previous oesophageal and gastric resection * Allergy to pimonidazole * Unable or unwilling to provide informed written consent * Pregnant women
Where this trial is running
London
- Imperial College NHS Healthcare Trust — London, United Kingdom (RECRUITING)
Study contacts
- Principal investigator: George Hanna — Imperial College London
- Study coordinator: Henry Douglas Robb, MBChB BSc (Hons) MSc MRCS
- Email: henry.robb19@imperial.ac.uk
- Phone: +44 (0) 207 594 8847
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: OESOPHAGO-GASTRIC CARCINOMA, voc, hypoxia, pimonidazole, oesophago-gastric carcinoma, volatile organic compounds, breath test